Vaginal discharge

Summary

Vaginal discharge (MONDO:0002770) is a disease and 12 clinical trials. Top therapeutic interventions include clotrimazole, fluconazole, and lidocaine hydrochloride. A subtype of vaginal disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 12

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	vaginal discharge
Mondo ID	MONDO:0002770
MeSH	D019522
DOID	DOID:3767
ICD-11	2123556104
NCIT	C50795
UMLS	C0227791
MedGen	65302
Is cancer (heuristic)	no

Also known as: Discharge, vaginal

Disease family

This is a subtype of vaginal disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › reproductive system disorder › female reproductive system disorder › vaginal disorder › vaginal discharge

Related subtypes (5): vaginitis, leukoplakia of vagina, vaginal neoplasm, polyp of vagina, vaginismus

Subtypes (1): leukorrhea

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 4 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Clotrimazole	Phase 3 (in late-stage trials)
Fluconazole	Phase 3 (in late-stage trials)
Metronidazole	Phase 3 (in late-stage trials)
Secnidazole	Phase 3 (in late-stage trials)

Clinical trials & evidence

Clinical trials

Clinical trials: 12.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	8
PHASE3	3
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03943823	PHASE4	TERMINATED	Postmenopausal Pessary Users: Estrogen Versus Trimosan
NCT02111629	PHASE3	COMPLETED	Safety and Clinical and Microbiological Efficacy of the Combination of Fluconazole and Secnidazole for the Treatment of Symptomatic Vaginal Discharge
NCT02713139	PHASE3	WITHDRAWN	Efficacy and Safety of the Association of Clotrimazole and Metronidazole in the Treatment of Vaginal Discharge From Different Etiologies.
NCT05201313	PHASE3	COMPLETED	Efficacy and Safety of the Application of Local Anaesthetic in Spray to Repair of 1st- 2nd Perineal Lacerations
NCT02898818	Not specified	RECRUITING	Vaginal and Oral Microbiome Crosstalk
NCT05977491	Not specified	ACTIVE_NOT_RECRUITING	Point-of-care Tests for Vaginal Discharge in Nepal
NCT06530186	Not specified	NOT_YET_RECRUITING	Evaluation of a Postcoital Sponge on Self-Reported Vaginal Health Parameters
NCT01347632	Not specified	COMPLETED	Study of How Bacterial Vaginosis and Its Treatment Affects Cervical and Vaginal Tissue
NCT02641717	Not specified	COMPLETED	Validity of Patient-Collected Wet Mounts
NCT04472377	Not specified	COMPLETED	HPV Typing Between Self- and Physician-sampled
NCT04885556	Not specified	UNKNOWN	Evaluation of a Novel Female Hygiene Device for Postcoital Discomfort
NCT07445958	Not specified	COMPLETED	In-Clinic Assessment of Vaginal Mucosal Safety Following Repetitive Use of the Livi Device

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CLOTRIMAZOLE	4	1
FLUCONAZOLE	4	1
LIDOCAINE HYDROCHLORIDE	4	1
MEPIVACAINE	4	1
SECNIDAZOLE	4	1
CHEMBL541521	0	1